Interventions for pityriasis rosea.

Area of Science:

• Dermatology
• Evidence-based medicine
• Pharmacology

Background:

• Pityriasis rosea is a common, self-limiting skin rash affecting young adults, characterized by scaly, itchy patches.
• Current treatment efficacy for pityriasis rosea remains uncertain, necessitating updated systematic reviews.
• This review is an update of a Cochrane Review first published in 2007.

Purpose of the Study:

• To systematically assess the effects of various interventions for managing pityriasis rosea in diagnosed individuals.
• To evaluate treatment efficacy based on rash improvement, itch reduction, and adverse events.

Main Methods:

• Conducted an updated systematic search of multiple databases up to October 2018.
• Included 14 randomized controlled trials (RCTs) involving 761 participants comparing interventions against placebo, no treatment, or other active compounds.
• Assessed key outcomes including rash improvement, itch resolution, and serious/minor adverse events.

Main Results:

• Oral acyclovir likely improves rash appearance (medical practitioner-rated) compared to placebo or no treatment, but evidence for itch relief is inconclusive.
• Erythromycin showed moderate-quality evidence for probable itch reduction compared to placebo, with low-quality evidence for rash improvement.
• Other interventions like clarithromycin and azithromycin demonstrated probable no difference in itch or rash improvement compared to placebo, with limited evidence on adverse events.

Conclusions:

• Oral acyclovir appears to be the most promising intervention for improving pityriasis rosea rash, though its impact on itch requires further investigation.
• Erythromycin may offer benefits for itch reduction, but overall evidence quality is limited by small study sizes and potential biases.
• Further research is recommended to explore optimal acyclovir dosing and the broader efficacy of antiviral agents in managing pityriasis rosea.